apitegromab tirzepatide A new phase 2 trial in Nature Medicine tested whether apitegromab, an investigational monoclonal antibody that selectively inhibits myostatin activation, could preserve lean mass during… Scholar Rock's drug helps Zepbound

The effects of treatment with L-carnitine of hypoglycemia in preterm AGA infants

doi:10.1038/s43856-024-00456-4

Low Wang said that long-term studies show that some people who have bariatric surgery gain the weight back just as people who stop taking these powerful diabetes drugs are likely also to gain the weight back if nothing else has changed

These data suggest that GIPR and GLP-1R are expressed on different cell populations in the AP, where GLP-1 also mediates nausea and avoidance 56

Small imbalances or weaknesses anywhere in this system create compensatory patterns that perpetuate injury

Lancet, 362(9398), 1828-1838